Shots:

• The P-III MONALEESA trials (MONALEESA-2- 3-7) involved assessing of Kisqali (ribociclib) + endocrine therapy vs endocrine therapy alone in patients with visceral metastases in pre- peri- and postmenopausal women with HR+/HER2- advanced breast cancer
• P-III MONALEESA study results: (MONALEESA-2- 3-7) mPFS (11.5 mos.- 16.5 mos.- 13.4 mos.)- mORR (53%- 48%- 50% vs 40%- 31%- 38%); w/o visceral disease ORR (59%- 49%- 52% vs 35%- 39%- 32%)
• Kisqali (ribociclib) is CDK4/6 (cyclin-dependent kinase) inhibitor and approved in the US & EU for postmenopausal women with HR+/HER2- LA or Mbreast cancer + aromatase inhibitor

Ref: Novartis | Image: The Irish Times